For a cell type to be useful in cancer adoptive immunotherapy it must be amenable to ex vivo expansion of potent effectors in a manner that avoids generation of regulatory or suppressive counterparts. With this in mind, numerous cell populations have been evaluated over the past 20 y, including dendritic cells, lymphokine activated killer (LAK) cells, tumor infiltrating lymphocytes, and positively selected natural killer (NK) cells. However, each method has limitations that have precluded widespread clinical adoption. For example, the difficulty in obtaining sufficient numbers of tumor infiltrating lymphocytes for most cancer types, and the expansion of regulatory T-cells in response to IL-2.
gdT lymphocytes have also been evaluated for ex vivo expansion for adoptive immunotherapy and equally confounding hurdles to overcome have been revealed. While gdT cell adoptive immunotherapy using existing technologies demonstrates modest but promising clinical effect, 1 new approaches are required for effective utilization of this unique population of cells.
There are a number of key differences between peripherally circulating gdT cells and the more abundant alpha beta T (abT) lymphocytes. Most notably, gdT cells recognize targets in an MHC independent manner, have innate killing activity against pathogens, and appear to respond to self-molecules that signal potential danger or cellular stress. Furthermore, they can differentiate into professional antigen presenting cells (pAPCs), expressing co-stimulatory molecules and presenting antigenic fragments for the primary stimulation of CD4
C and CD8
C ab T-cell responses. 2, 3 In the peripheral blood of individuals living outside areas of endemic parasitaemia, gdT cells expressing the Vg9Vd2 TCR are the commonest subset. In parts of Africa, however, the Vd1 C subset predominates, 4 and there is evidence of extra-thymic changes in gdT cell repertoire in response to environmental pathogen exposure. Until recently, almost all human gdT cell research focused on the Vg9Vd2 subset, due to its relative abundance in Western populations and ease of expanding large numbers of cells for study or adoptive transfer using phosphoantigen ligands of the Vg9Vd2 TCR. Deniger and colleagues 5, 6 demonstrated that polyclonal gdT cell expansion was possible using an engineered K562 cell line expressing CD86, CD64, 41BBL, and membrane bound IL-15. Using the same artificial antigen presenting cells (aAPC) coated in an antigdTCR antibody (Biolegend clone B1) we have shown that it is possible to generate >1,000 fold expansion of gdT cells from the blood of neuroblastoma patients within 1 mo, preserving the relative distributions of Vd1
C , Vd2 C and Vd1 neg /Vd2 neg gdT subtypes 7 ( Fig. 1 ).
Vd1
C and Vd1 neg /Vd2 neg gdT cells expanded using aAPCCB1 demonstrate many characteristics that recommend them for cellular immunotherapy over Vg9Vd2 C cells. Following adoptive transfer, less differentiated cells persist for longer in the recipient. Vd1
C and Vd1 neg / Vd2 neg gdT cells show a less differentiated pattern of CD27, CD45RA, and CD62L expression both before and after expansion with aAPCCB1 compared to Vd2 C gdT cells. PD-1 is a marker associated with Tcell exhaustion, and has been a key target in therapies aimed at overcoming immune checkpoints. solid and hematological malignancies, but with only a few exceptions this killing is significantly antibody dependent. 1 We showed that Vd1 C cytotoxicity against the same targets was independent of antibody and not attributable to alloreactivity, with killing efficiency equivalent or greater than the ability of Vd2
C gdT cells to kill opsonized target cells; Vd2 C cytotoxicity in the absence of opsonizing antibody was minimal. Based on these data, it is perhaps unsurprising that the published clinical trials of gdT cell immunotherapy, all of which used Vd2
C cell expansions and none of which combined the therapy with an antitumor antibody, showed only modest efficacy. 1, 9 Comparison of our recent studies with the work of Deniger et al. highlights differences in the innate cytolytic potential of Vd2 C gdT cells following expansion under differing conditions. These differences could be explained by different starting populations (umbilical cord blood vs. PBMC), different cytokines during expansion or different engagement of the gdTCR in the models used.
To be useful in cancer immunotherapy, an expanded effector population must possess certain characteristics. They require tumor tropism to infiltrate the tumor in sufficient numbers. Their memory phenotypes must be sufficiently na€ ıve to allow survival in the host following adoptive transfer, and their cytolytic activity must be specific for tumor cells. Therefore, despite the moderate clinical success of Vd2 C gdT cell based immunotherapy, there is an opportunity to explore the utility of non-Vd2 C gdT cells as adoptive transfer agents. These could be delivered either as selected populations or as polyclonal gdT cell preparations, which harness the different antigenic affinities, cytolytic and antigen presentation profiles of each subset.
Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed. Figure 1 . Use of artificial antigen presenting cells for unbiased expansion of blood gamma delta T lymphocytes. An antibody against the gamma delta T cell receptor tethered to the aAPC by the high affinity FcgReceptor, is responsible for forming an immunological synapse involving the gamma delta TCR.
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